Newest Rating: Horizon Pharma (NASDAQ:HZNP) Gets Better Rating From Citigroup. What Is The Stock Target?

November 28, 2016 - By Louis Casey

Newest Rating:  Horizon Pharma (NASDAQ:HZNP) Gets Better Rating From Citigroup. What Is The Stock Target?

Horizon Pharma (NASDAQ:HZNP) Upgrade

Citigroup boosted shares of Horizon Pharma (NASDAQ:HZNP) from a “Neutral” rating to “Buy” rating in a a report issued to clients and investors on Monday, 28 November.

Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage

Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $40 is the highest target while $21 is the lowest. The $28.33 average target is 33.70% above today’s ($21.19) stock price. Horizon Pharma has been the topic of 20 analyst reports since September 9, 2015 according to StockzIntelligence Inc. On Tuesday, November 10 the stock rating was maintained by Mizuho with “Buy”. As per Wednesday, June 29, the company rating was initiated by BMO Capital Markets. On Wednesday, January 6 the stock rating was reinitiated by Citigroup with “Neutral”. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) on Tuesday, September 13 with “Buy” rating. The firm earned “Mkt Outperform” rating on Wednesday, September 9 by JMP Securities. Mizuho maintained the stock with “Buy” rating in Tuesday, May 10 report. The company was initiated on Friday, October 9 by Mizuho. The firm has “Buy” rating given on Monday, June 6 by Goldman Sachs. On Tuesday, May 3 the stock rating was maintained by Mizuho with “Buy”. As per Tuesday, August 9, the company rating was maintained by Citigroup.

About 1.69M shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has risen 32.49% since April 25, 2016 and is uptrending. It has outperformed by 26.48% the S&P500.

Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on March, 6. They expect $0.52 EPS, 0.00% or $0.00 from last year’s $0.52 per share. HZNP’s profit will be $83.89M for 10.19 P/E if the $0.52 EPS becomes a reality. After $0.56 actual EPS reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.46 in Q2 2016. Its up 0.25, from 1.21 in 2016Q1. The ratio improved, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.

Proshare Advsr Lc accumulated 0.03% or 143,939 shares. Amer National Registered Invest Advisor Inc has 18,315 shares for 0.14% of their US portfolio. The Texas-based Moody Savings Bank Tru Division has invested 0.02% in Horizon Pharma PLC (NASDAQ:HZNP). Alps Advisors accumulated 0.03% or 225,270 shares. Wfg Advsr Limited Partnership has 0.02% invested in the company for 5,551 shares. Dimensional Fund Advisors Ltd Partnership holds 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 1.46 million shares. Manufacturers Life Ins The owns 108,847 shares or 0% of their US portfolio. Moreover, Aqr Cap Mngmt Ltd Liability Co has 0% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 86,846 shares. First Manhattan has invested 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Dekabank Deutsche Girozentrale holds 0.01% or 36,800 shares in its portfolio. Diam Limited accumulated 403,067 shares or 0.1% of the stock. Neumeier Poma Investment Counsel Ltd Liability Corporation last reported 1.28% of its portfolio in the stock. The Massachusetts-based Acadian Asset Management Limited Liability Corp has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP). Canada Pension Plan Inv Board last reported 0% of its portfolio in the stock. Ameritas Investment Prtn Incorporated last reported 12,572 shares in the company.

Insider Transactions: Since June 15, 2016, the stock had 0 insider purchases, and 2 sales for $500,280 net activity. SHERMAN JEFFREY W also sold $58,000 worth of Horizon Pharma PLC (NASDAQ:HZNP) on Tuesday, August 2. Nohria Virinder sold $442,280 worth of stock or 25,000 shares.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $3.42 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”

HZNP Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.

More important recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Fool.com which released: “Why Horizon Pharma PLC Jumped Higher Today” on November 07, 2016, also Fool.com published article titled: “Why Allergan, Horizon Pharma plc, and Pfizer All Spiked Wednesday”, Seekingalpha.com published: “Horizon Pharma Plc (HZNP) Q3 2016 Results – Earnings Call Transcript” on November 07, 2016. More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) was released by: Globenewswire.com and their article: “Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate …” with publication date: November 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>